STOCK TITAN

Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Equillium (Nasdaq: EQ) reported third-quarter financial results and began human testing of EQ504, with proof-of-mechanism data expected in Q2 2027. Third-quarter net loss widened to $4.583 million from $4.230 million a year earlier, while loss per share narrowed to $0.04 from $0.06. R&D expenses rose to $2.488 million; administrative expenses fell to $2.560 million.

Cash and equivalents totaled $53.322 million at September 30, 2026. An October 26 equity financing raised approximately $20 million gross, bringing supplemental pro forma cash to approximately $72.0 million, excluding subsequent cash use. Equillium expects funding to support planned operations into 2029. The Phase 1 trial involves approximately 70 healthy participants. Subject to supportive results, the company plans an ulcerative colitis proof-of-concept study in the second half of 2027.

Loading...
Loading translation...
13 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointOctober 26 equity financing delivered approximately $20 million in gross proceeds. 18% of market cap
  • Moderate pointEQ504 Phase 1 trial initiated in October 2026, with first participant dosing completed.
  • Moderate pointCash and equivalents increased to $53.322 million at September 30, 2026, versus $30.277 million at December 31, 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Equillium expects available funding to support currently planned operations into 2029.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Equillium plans an ulcerative colitis proof-of-concept study in the second half of 2027, subject to supportive results.
  • Moderate pointNine-month net loss narrowed to $14.587 million, or $0.14 per share, from $18.623 million, or $0.41.
7 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.EQ504 topline results, including proof-of-mechanism assessments, are expected in Q2 2027.
  • Minor pointNonclinical EQ504 data demonstrated effects on barrier integrity, inflammatory chemokine production and immune regulation.
  • Minor pointThird-quarter G&A expenses fell to $2.560 million from $3.274 million in 2025.
  • Minor pointThird-quarter other income, net, increased to $465,000 from $345,000 in 2025.
  • Minor pointNine-month R&D expenses fell to $8.228 million from $11.307 million in 2025.
  • Minor pointNine-month G&A expenses fell to $7.585 million from $8.365 million in 2025.
  • Minor pointNine-month other income, net, increased to $1.226 million from $1.049 million in 2025.

Negative

  • Moderate pointThird-quarter net loss widened to $4.583 million from $4.230 million; per-share loss narrowed to $0.04 from $0.06.
  • Moderate pointNine-month weighted-average common shares increased to 106,726,715 from 45,651,900 in 2025.
  • Minor pointThird-quarter R&D expenses rose to $2.488 million from $1.301 million in 2025.
  • Minor pointThird-quarter weighted-average common shares increased to 111,923,380 from 65,322,753 in 2025.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Planned ulcerative colitis study initiation remains subject to supportive Phase 1 results.

Key Figures

Phase 1 participants: approximately 70 healthy participants Proof-of-mechanism data: Q2 2027 Ulcerative colitis study: second half of 2027 +5 more
Phase 1 participants
approximately 70 healthy participants
EQ504 first-in-human study
Proof-of-mechanism data
Q2 2027
Topline data expected from the Phase 1 trial
Ulcerative colitis study
second half of 2027
Planned proof-of-concept study, subject to supportive results
October financing
approximately $20 million gross proceeds
Second tranche closed October 26, 2026
Cash and cash equivalents
$53.3 million
As of September 30, 2026
Pro forma cash
approximately $72.0 million
After estimated net proceeds from October funding
Cash runway
into 2029
Expected to fund currently planned operations
Net loss
$4.6 million, compared with $4.2 million
Third quarter 2026 versus third quarter 2025

Previous Earnings Reports

3 past events · Latest: Aug 13
Same Type 3 events
  1. Aug 13

    Q2 earnings update

    24h Move
    +17.4%

    Reported EQ504 Phase 1 plans, $57.2 million in cash, and runway into 2029.

  2. May 13

    Q1 earnings update

    24h Move
    +12.1%

    Outlined EQ504 Phase 1 plans and reported private-placement funding and runway into 2029.

  3. Nov 13

    Q3 earnings update

    24h Move
    +23.8%

    Planned an EQ504 Phase 1 study and disclosed private-placement funding with Q3 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pharmacokinetics, pharmacodynamics, cyp1a1, aryl hydrocarbon receptor
4 terms
pharmacokinetics medical
"safety, tolerability, pharmacokinetics and pharmacodynamics"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
pharmacodynamics medical
"safety, tolerability, pharmacokinetics and pharmacodynamics"
Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.
cyp1a1 medical
"including measurement of CYP1A1 expression"
CYP1A1 is a gene that encodes the cytochrome P450 1A1 enzyme, a member of the P450 family that chemically modifies foreign chemicals (xenobiotics) and some endogenous compounds in a first-step, “phase I” metabolism. It converts substances such as polycyclic aromatic hydrocarbons and certain drugs into more water‑soluble products or into reactive intermediates; genetic differences in CYP1A1 change how actively it metabolizes those compounds and can alter how the body handles environmental chemicals and some medications.
aryl hydrocarbon receptor medical
"novel small-molecule aryl hydrocarbon receptor (AhR) modulator"
Aryl hydrocarbon receptor (AHR) is a protein inside cells that detects certain environmental chemicals and helps turn genes on or off in response, like a smoke alarm that triggers specific reactions. It matters to investors because AHR influences how the body handles toxins and can be a target or safety concern in drug development, environmental liability assessment, and biomarker-driven regulatory decisions that affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027

Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20 million in gross financing received in October 2026

Cash runway expected into 2029

LA JOLLA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting recent progress with EQ504, its novel small-molecule aryl hydrocarbon receptor (AhR) modulator.

“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program,” said Bruce Steel, Chief Executive Officer of Equillium. “We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease. We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”

Recent Corporate and Clinical Highlights:

Initiated Phase 1 clinical trial of EQ504
In October 2026, Equillium initiated a first-in-human, randomized, double-blind, placebo-controlled study in Australia evaluating single and multiple ascending doses of EQ504 in approximately 70 healthy participants. The trial is designed to characterize safety, tolerability, pharmacokinetics and pharmacodynamics, and establish proof of mechanism of EQ504. The multiple ascending dose portion will include longitudinal gastrointestinal mucosal biopsies, including measurement of CYP1A1 expression, to assess AhR target engagement and localized biological activity in the gastrointestinal tract. Equillium expects to report topline data, including proof-of-mechanism assessments, in the second quarter of 2027. Subject to supportive results, Equillium plans to initiate a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.

Milestone Closing of $20 Million Financing
On October 26, 2026, concurrent with the first patient dosed in the Phase 1 clinical trial, Equillium closed the second tranche of the Company's previously announced August 2025 equity private placement agreement, resulting in aggregate gross proceeds of approximately $20 million.

Presented new nonclinical data further characterizing EQ504’s effects on epithelial barrier repair and immune regulation
Data presented at the 7th International AHR Conference demonstrated EQ504’s activity across complementary epithelial and immune pathways relevant to intestinal inflammation, including effects on barrier integrity, inflammatory chemokine production and immune regulation. Additional data presented at the 50th Anniversary La Jolla Immunology Conference further characterized coordinated AhR signaling across epithelial and immune compartments, supporting the potential of EQ504 to restore intestinal homeostasis through a differentiated, non-immunosuppressive mechanism of action.

Third Quarter 2026 Financial Results:

Cash and cash equivalents totaled $53.3 million as of September 30, 2026, compared to $33.1 million as of September 30, 2025. In October 2026, first participant dosing in the Phase 1 clinical trial of EQ504 triggered the second tranche of the Company’s previously announced August 2025 private placement agreement, resulting in approximately $20 million in additional funding. On a pro forma basis, after giving effect to the estimated net proceeds from this subsequent funding as if received on September 30, 2026, cash and cash equivalents would have been approximately $72.0 million. The pro forma amount is presented for supplemental informational purposes only and does not reflect cash used after September 30, 2026. Equillium believes that its cash and cash equivalents on the balance sheet as of September 30, 2026, together with the additional funding received in October 2026, are sufficient to fund its currently planned operations into 2029.  

Research and development (R&D) expenses for the third quarter of 2026 were $2.5 million, compared with $1.3 million for the same period in 2025.

General and administrative (G&A) expenses for the third quarter of 2026 were $2.6 million, compared with $3.3 million for the same period in 2025.

Net loss for the third quarter of 2026 was $4.6 million, or $(0.04) per basic and diluted share, compared with a net loss of $4.2 million, or $(0.06) per basic and diluted share for the same period in 2025.

About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal immunoregulatory mechanism of action without broad immune suppression, designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product. Equillium is also evaluating the potential of EQ504 for additional indications, including inflammatory lung diseases through inhaled formulations.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat serious autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential”, “will”, “designed to” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for reporting data from the Phase 1 study of EQ504; the potential benefits of EQ504, including its potential ability to address key epithelial and immune pathways involved in inflammatory disease; the anticipated initiation of a placebo-controlled proof-of-concept study, or the expected timeline for initiating such study, in patients with ulcerative colitis; the expected use of proceeds from the Milestone Closing; and Equillium’s expectations that its financial position and cash runway is sufficient to fund its currently planned operations into 2029. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and nonclinical studies; risks associated with relying on pro forma financial information; whether the results from clinical and nonclinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com


Equillium, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(unaudited)
  
  September 30,  December 31,
  2026  2025
Assets     
Cash and cash equivalents $53,322  $30,277
Prepaid expenses and other assets 1,818  952
Operating lease right-of-use assets 671  658
Total assets $55,811  $31,887
Current liabilities     
Accounts payable and other current liabilities $2,819  $2,934
Total current liabilities 2,819  2,934
Long-term operating lease liabilities 313  356
Total liabilities 3,132  3,290
Total stockholders' equity 52,679  28,597
Total liabilities and stockholders' equity $55,811  $31,887


Equillium, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(unaudited)
              
 Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
 2026   2025  2026   2025 
Operating expenses:             
Research and development$2,488   $1,301  $8,228   $11,307 
General and administrative2,560   3,274  7,585   8,365 
Total operating expenses5,048   4,575  15,813   19,672 
Loss from operations (5,048)   (4,575)  (15,813)   (19,672)
Total other income, net465   345  1,226   1,049 
Net loss$(4,583)  $(4,230) $(14,587)  $(18,623)
Net loss per share, basic and diluted$(0.04)   $(0.06) $(0.14)  $(0.41)
Weighted-average number of common shares outstanding, basic and diluted111,923,380   65,322,753  106,726,715   45,651,900 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Equillium report EQ504 Phase 1 results?

Equillium expects EQ504 Phase 1 topline data, including proof-of-mechanism assessments, in the second quarter of 2027. The trial began in October 2026 and evaluates approximately 70 healthy participants.

How much did Equillium raise in its October 2026 financing?

Equillium closed financing generating approximately $20 million in gross proceeds on October 26, 2026. This was the second tranche of its August 2025 equity private placement agreement, triggered by first participant dosing in the EQ504 Phase 1 trial.

How is Equillium testing whether EQ504 engages its biological target?

The multiple ascending dose portion of the Phase 1 trial includes repeated gastrointestinal tissue biopsies measuring CYP1A1 expression to assess engagement of the aryl hydrocarbon receptor target and localized biological activity. The randomized, double-blind, placebo-controlled study in Australia also evaluates safety, tolerability, drug exposure and biological effects.

Keep reading